OncoMatch/Clinical Trials/NCT07669467
Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer
Is NCT07669467 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies Nuvastatic 300 for fatigue related to cancer treatment.
Treatment: Nuvastatic 300
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
stable haemoglobin (≥ 9 g/dl) throughout the screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07669467 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages